"uuid:ID","rationale","label","instanceType","description","name","id"
"9e83b02b-6713-433a-89fa-8938ef7c7420","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","","StudyDesign","The main design for the study","Study Design 1","StudyDesign_1"
